News | May 24, 2025
Glenmark Pharma reports Q4 FY25 PAT at Rs. 346.6 Cr
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Adjusted Profit After Tax (PAT) for the year ended March 31, 2025 was at Rs. 1,389.4 crore
Q4 FY25 PAT stood at Rs. 90.7 crore as compared to Rs.77.6 crore in Q4 FY24
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
IGI recently completed the dose-escalation portion of its Phase 1 clinical study in patients with heavily pretreated multiple myeloma
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025
The Subsidiary has received one inspectional observation in Form 483
According to IQVIATM sales data for the 12-month period ending February 2025, the Adderall Tablets, 5 mg, 10 mg, 15 mg, 20 mg, and 30 mg market3 achieved annual sales of approximately $421.7 million.
Rising demands and advancements in eye care drive growth
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
Subscribe To Our Newsletter & Stay Updated
